Financials
Financial year 2025
MEDPACE BELGIUM from Leuven, company number BE0877865242, closed financial year 2025 with a result of € 753,286 after tax. For that financial year MEDPACE BELGIUM recorded revenue of € 21.6 million and equity of € 3.4 million. Compared with financial year 2024, the result moved from € 672,197 to € 753,286. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 3.4 million
▲ 28% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 753,286
▲ 12% vs 2024
Profit after tax over the fiscal year.
€ 1.5 million
▼ 18% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 3.4 million.
People and assets in 2025
178.2
▲ 7.8 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 17.7 million
▲ 8% vs 2024
€ 99,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1.3 million
▼ 19% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1.7 million
▲ 66% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 156 days on average.
€ 3.6 million
▲ 5% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | € 16,638,650 | € 19,564,400 | € 21,626,843 | ▲ 11% |
| Gross margin | € 11,264,177 | - | - | - | |
| Profit after taxes | € 339,291 | € 587,672 | € 672,197 | € 753,286 | ▲ 12% |
| Equity | € 1,420,701 | € 2,008,373 | € 2,680,570 | € 3,433,856 | ▲ 28% |
| Total debts | € 4,174,231 | € 4,717,574 | € 4,652,823 | € 5,448,692 | ▲ 17% |
| Cash | € 666,507 | € 1,775,486 | € 1,855,506 | € 1,521,514 | ▼ 18% |
| Retained profit | € 1,408,301 | € 1,995,973 | € 2,666,310 | € 3,419,596 | ▲ 28% |
| Balance sheet total | € 5,594,932 | € 6,725,947 | € 7,333,393 | € 8,882,549 | ▲ 21% |
| Employees (FTE) | 119.8 | 144.4 | 170.4 | 178.2 | ▲ 7.8 |
Key figures of MEDPACE BELGIUM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDPACE BELGIUM?
What happened at MEDPACE BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 753,286 (▲ 12% vs 2024). filed late Source: NBB ↗
- John Thomas Wynne II became a director. NBB
- Kevin Michael Brady became a director. NBB
- Brad William Hansman became a director. NBB
- Stephen Paul Ewald became a director. NBB
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
In short
From € 339,291 profit in 2022 to € 753,286 profit in 2025.
Paid € 1.2 million in corporate taxes since 2022.
Best year ever: 2025, with € 753,286 profit.
On average € 94,000 of value added per employee in 2022.
A new publication or filing at MEDPACE BELGIUM? We notify you, reason included.
Follow MEDPACE BELGIUMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind MEDPACE BELGIUM are John Thomas Wynne II, Kevin Michael Brady, Stephen Paul Ewald and Brad William Hansman. The shares are held by Medpace Europe Holding BV.
Directors
According to the 2025 annual accounts
John Thomas Wynne II
Director
since 2026
Kevin Michael Brady
Director
since 2026
Stephen Paul Ewald
Director
since 2021
Brad William Hansman
Director
since 2026
Shareholders
Medpace Europe Holding BV
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Technologielaan 11
3001 Leuven
Technologielaan 19
3001 Leuven
Active since 6 November 2006
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0877.865.242
- VAT number
- BE 0877.865.242
- Registered office
- Technologielaan 11, 3001 Leuven
- Names & denominations
- MEDPACE BELGIUM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 13 December 2005
- Peppol
- Active · Active since 22 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Activiteiten van medische beeldvorming en medische laboratoria
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten van medische laboratoria